Uniplan Investment Counsel’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Uniplan Investment Counsel’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-292	Closed	-$1.34M	–	127
2023 Q2	$1.34M	Sell	292 -1	-0.3%	-$3.47K	0.1%	114
2023 Q1	$778K	Sell	293 -14	-5%	-$41K	0.05%	117
2022 Q4	$799K	Sell	307 -340	-53%	-$1.19M	0.06%	119
2022 Q3	$2.56M	Sell	647 -4	-0.6%	-$15.7K	0.2%	93
2022 Q2	$1.7M	Buy	651 +244	+60%	+$636K	0.12%	114
2022 Q1	$1.31M	Buy	407 +3	+0.7%	+$12.9K	0.08%	125
2021 Q4	$2.53M	Buy	404 +1	+0.2%	+$7.68K	0.14%	109
2021 Q3	$3.73M	Sell	403 -1	-0.2%	-$8.59K	0.23%	79
2021 Q2	$4.09M	Buy	404 +6	+2%	+$98.6K	0.24%	82
2021 Q1	$7.63M	Sell	398 -104	-21%	-$1.21M	0.49%	43
2020 Q4	$3.04M	Sell	502 -27	-5%	-$106K	0.21%	87
2020 Q3	$1.9M	Buy	529 +176	+50%	+$632K	0.13%	102
2020 Q2	$1.37M	Sell	353 -186	-35%	-$617K	0.1%	108
2020 Q1	$1.01M	Buy	539 +366	+212%	+$1.36M	0.08%	109
2019 Q4	$890K	Buy	173 +2	+1%	+$7.67K	0.05%	123
2019 Q3	$604K	Sell	171 -9	-5%	-$54.2K	0.04%	120
2019 Q2	$1.52M	Buy	+180	New	+$1.89M	0.1%	110

Other funds holding SEEL

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Uniplan Investment Counsel's SEEL Position: Q3 2023 in Review

Uniplan Investment Counsel sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2023, closing a stake of 292 shares — an estimated $1.34M sold.

Uniplan Investment Counsel first reported a position in SEEL in Q2 2019 and held it in 17 quarters. The position peaked at $7.63M in Q1 2021. 67 funds tracked by Wall St. Rank hold SEEL as of Q3 2023.

Uniplan Investment Counsel reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Uniplan Investment Counsel sold 292 Seelos Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.34M.
Uniplan Investment Counsel first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 17 quarters.
Uniplan Investment Counsel's Seelos Therapeutics, Inc. Common Stock position peaked at $7.63M in Q1 2021.
67 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Uniplan Investment Counsel's 13F filing for Q3 2023, filed 14 Nov 2023.